Aopeng Medical

Aopeng Medical has positioned itself as a pioneer in pan-vascular interventional robotics, developing the ALLVAS™ system as what the company describes as the world’s first universal endovascular intervention robot. Founded in 2017 and headquartered in Shanghai’s Zhangjiang Science City, the company has accumulated over 100 patents and completed multiple first-in-human clinical trials across different vascular territories.

Company Overview

Aopeng Medical emerged from a vision to transform traditional minimally invasive interventional procedures through robotic assistance and artificial intelligence. The company operates as a Shanghai Municipal Specialized and Sophisticated Enterprise (“专精特新”) and serves as a national project undertaker for China’s “New Generation Artificial Intelligence” initiative.

The founding team brings together expertise from leading Chinese institutions including Shanghai Jiao Tong University and University of Science and Technology of China, with an academician serving in a leadership capacity. This academic foundation has enabled the company to develop proprietary technologies across robot architecture design, actuator engineering, force feedback mechanisms, and AI-driven surgical planning.

Aopeng Medical has articulated its ambition to become “the da Vinci of vascular intervention,” pursuing a platform approach that differentiates it from single-specialty competitors. By April 2025, the company had secured approximately $43.7 million in cumulative funding across multiple rounds, with Series C financing led by Jinan International Medical Center Industrial Development and co-invested by Sunland Capital.

Core Products

ALLVAS™ Endovascular Intervention Robot

The ALLVAS™ system represents Aopeng Medical’s flagship product, designed as an open platform capable of addressing interventional procedures across eight vascular territories: coronary, peripheral, neurovascular, aortic, tumor ablation, and others. This breadth distinguishes it from existing vascular robots that typically focus on single specialties like coronary PCI.

Key technical specifications include:

• Positioning Precision: 0.1mm accuracy in 3D vascular reconstruction
• Force Feedback: Proprietary electromagnetic damping rotational feedback handle
• Operational Accuracy: Sub-millimeter level instrument manipulation
• Radiation Reduction: Over 90% reduction in operator radiation exposure
• Localization Rate: Over 90% domestic component sourcing

The system employs multi-modal image fusion technology to generate patient-specific vascular digital models, enabling real-time intraoperative simulation. Clinical data indicates a 40% reduction in complication rates and 98.7% procedural success rate in evaluated cases.

Technology & Innovation

Aopeng Medical has built its technical platform around three core pillars:

Open Architecture Platform: Unlike competitors focused on single vascular beds, ALLVAS™ accommodates diverse catheter and guidewire systems across specialties. This flexibility allows deployment in cardiology, vascular surgery, neurology, neurosurgery, and interventional radiology departments.

AI Integration: The system incorporates deep learning algorithms trained on surgical data to optimize procedure planning and provide real-time decision support. Automatic lesion identification and optimal pathway calculation represent key AI-enabled features.

5G Remote Surgery Capability: In 2023, Aopeng Medical completed China’s first 5G remote coronary intervention procedure with end-to-end latency below 80 milliseconds, demonstrating potential for extending specialist expertise to underserved regions.

The company has created three world-first robotic procedures: neurovascular thrombectomy, vena cava filter implantation/retrieval, and aortic stent graft deployment.

Clinical Progress

ALLVAS™ has progressed through multiple clinical milestones:

• 2021: First-in-human robot-assisted TEVAR and EVAR (thoracic and abdominal endovascular aortic repair) at Shanghai Changhai Hospital
• 2021: First-in-human robot-assisted iliac artery intervention
• 2023: China’s first 5G remote coronary PCI procedure
• 2025: Coronary PCI indication multicenter clinical trial completed, entered NMPA registration phase

The system has received inclusion in China’s National Health Commission Innovative Medical Device Catalog, providing regulatory pathway advantages.

Market Presence

Aopeng Medical operates primarily in the Chinese market while positioning for international expansion. The company targets tertiary hospitals with high-volume interventional programs, where the ALLVAS™ platform can serve multiple departments from a single installation.

The vascular interventional robot market remains nascent globally, with limited approved products compared to the more mature laparoscopic surgery segment. As of early 2025, no pan-vascular interventional robot had received NMPA approval in China, creating a first-mover opportunity for companies completing registration.

Key Milestones

• 2017: Company founded in Shanghai
• 2020: Completed Series A financing (~CNY 100M)
• 2021: First-in-human clinical trials for EVAR/TEVAR and iliac intervention
• 2023: Completed China’s first 5G remote coronary intervention
• 2025: Series C financing (~CNY 100M), NMPA registration submission for coronary PCI

Frequently Asked Questions

What vascular procedures can ALLVAS™ perform?

ALLVAS™ is designed as a universal platform covering coronary artery intervention (PCI), peripheral vascular intervention, neurovascular procedures (thrombectomy), aortic stent graft deployment (TEVAR/EVAR), and tumor embolization. This multi-specialty capability differentiates it from single-indication competitors.

Has Aopeng Medical received NMPA approval?

As of early 2026, ALLVAS™ has completed multicenter clinical trials for coronary PCI and entered the NMPA registration phase. The product has been included in China’s Innovative Medical Device Catalog. Full market approval is pending.

Is Aopeng Medical publicly traded?

Aopeng Medical remains a privately held company. The company has completed Series C financing as of April 2025, with total raised funding approximately $43.7 million.